| Market Cap | 1.26B | P/E | - | EPS this Y | -12.10% | Ern Qtrly Grth | - |
| Income | -389.9M | Forward P/E | -3.06 | EPS next Y | 3.20% | 50D Avg Chg | 20.00% |
| Sales | - | PEG | 0.13 | EPS past 5Y | - | 200D Avg Chg | -20.00% |
| Dividend | N/A | Price/Book | 3.20 | EPS next 5Y | -19.00% | 52W High Chg | -57.00% |
| Recommedations | 2.00 | Quick Ratio | 4.55 | Shares Outstanding | 157.80M | 52W Low Chg | 47.00% |
| Insider Own | 0.47% | ROA | -35.58% | Shares Float | 119.90M | Beta | 0.38 |
| Inst Own | 103.62% | ROE | -71.41% | Shares Shorted/Prior | 19.08M/18.24M | Price | 7.98 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 5,129,501 | Target Price | 23.00 |
| Oper. Margin | - | Earnings Date | Feb 22 | Volume | 2,642,387 | Change | -1.85% |
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
| Goldman Sachs | Neutral | Dec 9, 22 |
| Benchmark | Neutral | Dec 9, 22 |
| JMP Securities | Market Outperform | Nov 21, 22 |
| Piper Sandler | Neutral | Nov 21, 22 |
| Chardan Capital | Buy | Nov 21, 22 |
| HC Wainwright & Co. | Buy | Nov 18, 22 |
| Guggenheim | Neutral | Oct 31, 22 |
| Baird | Outperform | Aug 5, 22 |
| Goldman Sachs | Buy | Jul 1, 22 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Rothbaum Wayne P. | Director Director | Dec 02 | Buy | 6.50 | 10,000,000 | 65,000,000 | 18,067,333 | 12/02/22 |
| Vogt Frederick G | Interim CEO & Genera.. Interim CEO & General Counsel | Nov 28 | Buy | 5.98 | 1,000 | 5,980 | 2,000 | 11/28/22 |
| MCPEAK MERRILL A | Director Director | Nov 28 | Buy | 6.18 | 10,000 | 61,800 | 228,633 | 11/28/22 |
| Dukes Iain D. | Director Director | Nov 23 | Buy | 6.10 | 10,000 | 61,000 | 22,000 | 11/28/22 |
| MCPEAK MERRILL A | Director Director | May 31 | Buy | 6.82 | 20,000 | 136,400 | 218,633 | 06/02/22 |
| Maynard Ryan D | Director Director | May 31 | Buy | 6.745 | 7,500 | 50,588 | 7,500 | 06/02/22 |
| WEISER MICHAEL | Director Director | May 31 | Buy | 6.8 | 10,000 | 68,000 | 112,632 | 06/02/22 |
| Vogt Frederick G | Interim CEO & Genera.. Interim CEO & General Counsel | Jun 01 | Buy | 6.44 | 1,000 | 6,440 | 1,000 | 06/02/22 |
| Rothbaum Wayne P. | Director Director | May 31 | Buy | 6.6 | 1,000,000 | 6,600,000 | 8,067,333 | 06/02/22 |